Clinical Trial Update: Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating solifenacin succinate (VESICARE) for urinary incontinence in Parkinson's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Urinary Incontinence

Drugs mentioned

• Vesicare (solifenacin succinate)

Snippet

Sponsor: University of South Florida | Conditions: Urinary Incontinence, Parkinson's Disease | Phase 4 | Status: WITHDRAWN